Expression of granzyme M and other cytotoxic proteins in cases studied
| . | TIA-1 (%) . | Granzyme B (%) . | Granzyme M (%) . | Overall* (%) . |
|---|---|---|---|---|
| GM+CtxP+lymphomas | ||||
| Nasal NK/TCL | 25/25 (100) | 25/25 (100) | 25/25 (100) | 25/25 (100) |
| γδ TCL | 5/5 (100) | 5/5 (100) | 5/5 (100) | 5/5 (100) |
| Hepatosplenic | 3/3 (100) | 3/3 (100) | 3/3 (100) | 3/3 (100) |
| Other locations | 2/2 (100) | 2/2 (100) | 2/2 (100) | 2/2 (100) |
| Intestinal TCL | 26/27 (96) | 21/27 (78) | 22/27 (85) | 26/27 (96) |
| CD56− | 20/21 (95) | 19/21 (90) | 20/21 (95) | 20/21 (95) |
| CD56+ | 6/6 (100) | 2/6 (33) | 2/6 (33) | 6/6 (100) |
| GM−CtxP+lymphomas | ||||
| ALCL | 32/49 (65) | 32/49 (65) | 3/49 (6) | 39/49 (80) |
| Cutaneous | 3/10 (30) | 3/10 (30) | 2/10 (20) | 6/10 (60) |
| Systemic | 29/39 (74) | 29/39 (74) | 1/39 (3) | 33/39 (85) |
| Panniculitis-like TCL | 18/18 (100) | 18/18 (100) | 2/18 (11) | 18/18 (100) |
| CD56− | 17/17 (100) | 17/17 (100) | 1/17 (6) | 17/17 (100) |
| CD56+ | 1/1 (100) | 1/1 (100) | 1/1 (100) | 1/1 (100) |
| GM−CtxP−lymphomas | ||||
| AILT | 1/23 (4) | 1/23 (4) | 0/23 (0) | 1/23 (4) |
| MF/SS | 2/31 (6) | 1/31 (3) | 1/31 (3) | 2/31 (6) |
| “Mixed” lymphomas | ||||
| TCL unspecified | 12/36 (33) | 13/36 (36) | 14/36 (39) | 15/36 (42) |
| Nodal | 8/27 (30) | 9/27 (33) | 9/27 (33) | 9/27 (33) |
| Extranodal | 4/9 (44) | 4/9 (44) | 5/9 (56) | 6/9 (67) |
| Total | 121/214 (57) | 116/214 (54) | 72/214 (34) | 131/214 (61) |
| . | TIA-1 (%) . | Granzyme B (%) . | Granzyme M (%) . | Overall* (%) . |
|---|---|---|---|---|
| GM+CtxP+lymphomas | ||||
| Nasal NK/TCL | 25/25 (100) | 25/25 (100) | 25/25 (100) | 25/25 (100) |
| γδ TCL | 5/5 (100) | 5/5 (100) | 5/5 (100) | 5/5 (100) |
| Hepatosplenic | 3/3 (100) | 3/3 (100) | 3/3 (100) | 3/3 (100) |
| Other locations | 2/2 (100) | 2/2 (100) | 2/2 (100) | 2/2 (100) |
| Intestinal TCL | 26/27 (96) | 21/27 (78) | 22/27 (85) | 26/27 (96) |
| CD56− | 20/21 (95) | 19/21 (90) | 20/21 (95) | 20/21 (95) |
| CD56+ | 6/6 (100) | 2/6 (33) | 2/6 (33) | 6/6 (100) |
| GM−CtxP+lymphomas | ||||
| ALCL | 32/49 (65) | 32/49 (65) | 3/49 (6) | 39/49 (80) |
| Cutaneous | 3/10 (30) | 3/10 (30) | 2/10 (20) | 6/10 (60) |
| Systemic | 29/39 (74) | 29/39 (74) | 1/39 (3) | 33/39 (85) |
| Panniculitis-like TCL | 18/18 (100) | 18/18 (100) | 2/18 (11) | 18/18 (100) |
| CD56− | 17/17 (100) | 17/17 (100) | 1/17 (6) | 17/17 (100) |
| CD56+ | 1/1 (100) | 1/1 (100) | 1/1 (100) | 1/1 (100) |
| GM−CtxP−lymphomas | ||||
| AILT | 1/23 (4) | 1/23 (4) | 0/23 (0) | 1/23 (4) |
| MF/SS | 2/31 (6) | 1/31 (3) | 1/31 (3) | 2/31 (6) |
| “Mixed” lymphomas | ||||
| TCL unspecified | 12/36 (33) | 13/36 (36) | 14/36 (39) | 15/36 (42) |
| Nodal | 8/27 (30) | 9/27 (33) | 9/27 (33) | 9/27 (33) |
| Extranodal | 4/9 (44) | 4/9 (44) | 5/9 (56) | 6/9 (67) |
| Total | 121/214 (57) | 116/214 (54) | 72/214 (34) | 131/214 (61) |
Positive for at least one cytotoxic cell-associated protein.